Five-year experience with a triple drug protocol in renal transplantation.
Pallardó
L M
LM
Department of Nephrology, Hospital Universitario La Fe, Valencia, Spain.
Sánchez
J
J
García
J
J
Puig
N
N
Sánchez
P
P
Górriz
J L
JL
Cruz
J M
JM
D000704:Analysis of Variance; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001803:Blood Transfusion; D016572:Cyclosporine / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006084:Graft Rejection; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D008775:Methylprednisolone / Q000627:therapeutic use*; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use*; D012189:Retrospective Studies; D013997:Time Factors
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D016572:Cyclosporine; D011241:Prednisone; D008775:Methylprednisolone